ChinaSecurities

CHENGDU, China -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and Western Pharmaceuticals based in Chengdu, China, today announced that management will host a conference call to discuss its fiscal 2010 second quarter results at 4:30 p.m. ET on Monday, February 8, 2010. Financial results will also be released that day.

Interested parties may access the call by dialing +1-877-941-8418 from within the United States, or +1-480-629-9809 if calling internationally. The conference ID is 4207607. It is advisable to dial in approximately 5-10 minutes prior to the start of the call. A replay will be available through February 22, 2010 and can be accessed by dialing +1-800-406-7325 (U.S.), +1-303-590-3030 (Int'l), passcode 4207607.

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://viavid.net/dce.aspx?sid=00007061 . To access the web cast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player please visit:

http://www.microsoft.com/windows/windows... .

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. Tianyin currently has 48 SFDA approved products, 41 which are manufactured and marketed. 22 of these products are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has also maintains a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 730 salespeople. The Company is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:
                  
                      For the Company:
                       Allen Tang, Ph.D., MBA, Assistant to the CEO China
                       Tel:   +86-158-2122-5642
                       Email: Allen.y.tang@gmail.com
                  
                      Investors:
                       Mr. Matthew Hayden, HC International
                       Tel:   +1-561-245-5155
                       Email: matt.hayden@hcinternational.net
                  

SOURCE Tianyin Pharmaceutical Co., Inc.